Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, Christopher Lao, CL Cowey, D Schadendorf, J Wagstaff, R Dummer, PF Ferrucci, M Smylie, D Hogg, A Hill, I Márquez-Rodas, J Haanen, M Guidoboni, M Maio, P Schöffski, . Carlino, C Lebbé, G McArthur, PA Ascierto, GA Daniels, GV Long, L Bastholt, JI Rizzo, A Balogh, A Moshyk, FS Hodi, JD Wolchok
Combined nivolumab and ipilimumab in melanoma metastatic to the brain
HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, NI Khushalani, K Lewis, Christopher Lao, MA Postow, MB Atkins, . Ernstoff, DA Reardon, I Puzanov, RR Kudchadkar, RP Thomas, A Tarhini, AC Pavlick, J Jiang, A Avila, S Demelo, K Margolin
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, CL Cowey, Christopher Lao, J Wagstaff, D Schadendorf, PF Ferrucci, M Smylie, R Dummer, A Hill, D Hogg, J Haanen, . Carlino, O Bechter, M Maio, I Marquez-Rodas, M Guidoboni, G McArthur, C Lebbé, PA Ascierto, GV Long, J Cebon, J Sosman, MA Postow, MK Callahan, D Walker, L Rollin, R Bhore, FS Hodi, J Larkin
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma
TM Atkinson, JL Hay, A Shoushtari, Y Li, DJ Paucar, SC Smith, RR Kudchadkar, A Doyle, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, GP Linette, TF Gajewski, J Lutzky, DH Lawson, Christopher Lao, PJ Flynn, . Albertini, T Sato, K Lewis, B Marr, DH Abramson, MA Dickson, GK Schwartz, RD Carvajal
Load more…